PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma

Leukemia

Volumn 28, Issue 1, 2014, Pages 213-216

  Dimitrova, L ^a   Seitz, V ^a   Hecht, J ^a   Lenze, D ^a   Hansen, P ^a   Szczepanowski, M ^b   Ma, L ^b,c   Oker, E ^a   Sommerfeld, A ^a   Jundt, F ^a   Klapper, W ^b   Hummel, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD19 ANTIGEN; CD79A ANTIGEN; DNA; JANUS KINASE; MIFEPRISTONE; STAT PROTEIN; TRANSCRIPTION FACTOR PAX5; TRICHOSTATIN A;

APOPTOSIS; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BINDING AFFINITY; BINDING SITE; BLK GENE; BLNK GENE; CD19 GENE; CD79A GENE; CELL CYCLE REGULATION; CHROMATIN IMMUNOPRECIPITATION; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE; GENE OVEREXPRESSION; GENE TARGETING; GERMINAL CENTER; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LETTER; LUCIFERASE ASSAY; LYMPHOCYTE PROLIFERATION; LYMPHOMA CELL LINE; NUCLEAR LOCALIZATION SIGNAL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STABLE TRANSFECTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; HODGKIN DISEASE; HUMANS; PHENOTYPE;

EID: 84891863713     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.211     Document Type: Letter

References (14)

1. Fuxa M, Busslinger M. Reporter gene insertions reveal a strictly B lymphoidspecific expression pattern of Pax5 in support of its B cell identity function. J Immunol 2007; 178: 3031-3037. (Pubitemid 46333183)
2. Foss HD, Reusch R, Demel G, Lenz G, Anagnostopoulos I, Hummel M et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999; 94: 3108-3113. (Pubitemid 29512717)
3. Kuppers R, Klein U, Schwering I, Distler V, Brauninger A, Cattoretti G et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 2003; 111: 529-537. (Pubitemid 36228010)
4. Horcher M, Souabni A, Busslinger M. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 2001; 14: 779-790. (Pubitemid 32592424)
5. Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007; 449: 473-477. (Pubitemid 47509547)
6. Janz M, Hummel M, Truss M, Wollert-Wulf B, Mathas S, Johrens K et al. Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood 2006; 107: 2536-2539. (Pubitemid 43345579)
7. Hopken UE, Foss HD, Meyer D, Hinz M, Leder K, Stein H et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 2002; 99: 1109-1116. (Pubitemid 34547061)
8. Atayar C, Poppema S, Blokzijl T, Harms G, Boot M, van den Berg A. Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas. Am J Pathol 2005; 166: 127-134. (Pubitemid 40051666)
9. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1-14.
10. Tiacci E, Doring C, Brune V, van Noesel CJ, Klapper W, Mechtersheimer G et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012; 120: 4609-4620.
11. Bohle V, Doring C, Hansmann ML, Kuppers R. Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma. Leukemia 2013; 27: 671-679.
12. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
13. Seitz V, Thomas PE, Zimmermann K, Paul U, Ehlers A, Joosten M et al. Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation. Haematologica 2011; 96: 863-870.
14. McManus S, Ebert A, Salvagiotto G, Medvedovic J, Sun Q, Tamir I et al. The transcription factor Pax5 regulates its target genes by recruiting chromatinmodifying proteins in committed B cells. EMBO J 2011; 30: 2388-2404.